About: Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
Creator	Fernandes, Santos Hoff, Paulo Aguiar, Samuel Carvalho, Elisângela Coimbra, Felipe Coutinho, Anelisa Crosara, Marcela Filho, Duílio Gansl, Rene Prolla, Gabriel Riechelmann, Rachel Weschenfelder, Rui Chaves Andrade, Aline D', Renata Dos, Gustavo Florinda, Juliana Peixoto, Alpino Rego, M
Source	Medline; PMC
abstract	PURPOSE: As of 2020, the world is facing the great challenge of the COVID-19 (Coronavirus disease 2019) pandemic, caused by the SARS-CoV-2 virus. While the overall mortality is low, the virus is highly virulent and may infect millions of people worldwide. This will consequently burden health systems, particularly by those individuals considered to be at high risk of severe complications from COVID-19. Such risk factors include advanced age, cardiovascular and pulmonary diseases, diabetes and cancer. However, few data on the outcomes of cancer patients infected by SARS CoV-2 exist. Therefore, there is a lack of guidance on how to manage cancer patients during the pandemic. We sought to propose specific recommendations about the management of patients with gastrointestinal malignancies. METHODS: The Brazilian Gastrointestinal Tumours Group board of directors and members sought up-to-date scientific literature on each tumour type and discussed all recommendations by virtual meetings to provide evidence-based—and sometimes, expert opinion—recommendation statements. Our objectives were to recommend evidence-based approaches to both treat and minimise the risk of COVID-19 for cancer patients, and simultaneously propose how to decrease the use of hospital resources at a time these resources need to be available to treat COVID-19 patients. RESULTS: Overall and tumour-specific recommendations were made by stage (including surgical, locoregional, radiotherapy, systemic treatments and follow-up strategies) for the most common gastrointestinal malignancies: esophagus, gastric, pancreas, bile duct, hepatocellular, colorectal, anal cancer and neuroendocrine tumours. CONCLUSIONS: Our recommendations emphasise the importance of treating cancer patients, using the best evidence available, while simultaneously taking into consideration the world-wide health resource hyperutilisation to treat non-cancer COVID-19 patients.
has issue date	2020-05-22(xsd:dateTime)
bibo:doi	10.3332/ecancer.2020.1048
bibo:pmid	32565901
has license	cc-by
sha1sum (hex)	a6b7aad6a5211390692e281f76a2797204ecb348
schema:url	https://doi.org/10.3332/ecancer.2020.1048
resource representing a document's title	Evidence-based recommendations for gastrointestinal cancers during the COVID-19 pandemic by the Brazilian Gastrointestinal Tumours Group
has PubMed Central identifier	PMC7289615
has PubMed identifier	32565901
schema:publication	Ecancermedicalscience
resource representing a document's body	covid:a6b7aad6a5211390692e281f76a2797204ecb348#body_text
is schema:about of	named entity 'GUIDANCE' named entity 'ABOUT' named entity 'VIRULENT' named entity 'INFECTED' named entity 'SARS' named entity 'MALIGNANCIES' named entity 'DATA' named entity 'malignancies' named entity 'Coronavirus disease 2019' named entity 'COVID-19' named entity 'SARS CoV' named entity 'metastatic' named entity 'metastatic disease' named entity 'NEC' named entity 'exposure to the virus' named entity 'adverse events' named entity 'squamous cell' named entity 'capecitabine' named entity 'metastatic disease' named entity '5-FU' named entity 'monoclonal antibodies' named entity 'metastatic disease' named entity 'intra-abdominal' named entity 'Histological' named entity 'cisplatin' named entity 'lymphovascular invasion' named entity 'nonprofit organisation' named entity 'HIV-infected patients' named entity 'gastrointestinal' named entity 'cardiovascular' named entity 'Tumours' named entity 'adenocarcinomas' named entity 'colorectal cancer' named entity 'paclitaxel' named entity 'minimally invasive surgeries' named entity 'liver' named entity 'radiotherapy' named entity 'Radiation dose' named entity 'minimally invasive surgeries' named entity 'aerosol' named entity 'systemic therapy' named entity 'radiofrequency ablation' named entity 'colon cancer' named entity 'chemotherapy' named entity 'systemic therapy' named entity 'neoadjuvant therapy' named entity 'anal verge' named entity 'colon cancer' named entity 'health care professionals' named entity 'ileostomy' named entity 'lymph nodes' named entity 'microsatellite instability' named entity 'HER2' named entity 'regorafenib' named entity 'oncological' named entity 'metastatic disease' named entity 'toxicity' named entity 'CAPOX' named entity 'opportunistic infections' named entity 'subclinical' named entity 'coronavirus' named entity 'chemotherapy' named entity 'Child-Pugh score' named entity 'metastasis'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software